Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Dialysis

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Next-generation kidney tissue analysis - spatial omics and digital pathology.

Nature reviews. Nephrology·2026

Same author

Novel <i>GPRC5B</i>::<i>PRKCA</i> gene fusion in an unclassifiable low-grade glioneuronal tumor.

Neuro-oncology advances·2026

Same author

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.

Cancer science·2026

Same author

Cross-Cultural Adaptation and Validation of the Japanese Charité Alarm Fatigue Questionnaire (CAFQa) Among ICU Nurses and Physicians: A Multicentre Study.

Nursing in critical care·2026

Same author

Proximal Tubule-Derived Semaphorin 3C Promotes Fibrosis in Adenine-Induced Tubulointerstitial Nephritis.

Kidney360·2026

Same author

Anticoagulation therapy for Lemierre syndrome: a comprehensive review and individual participant data analysis.

Thrombosis journal·2026

Search research articles

Related Experiment Video

Updated: May 27, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Cancer diagnosis and prognosis after initiation of hemodialysis: multicenter Japan CANcer and DialYsis (J-CANDY)

Naoya Toriu^1,2, Shinya Yamamoto¹, Takeshi Matsubara¹

¹Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Clinical Kidney Journal

|February 17, 2025

Summary

Cancer patients on hemodialysis (kidney dialysis) have similar survival rates to general cancer patients when treated with surgery. Early diagnosis through screening improves outcomes for these vulnerable individuals.

Keywords:

cancer hemodialysis prognosis surgery

More Related Videos

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

Related Experiment Videos

Last Updated: May 27, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

Area of Science:

Oncology
Nephrology
Public Health

Background:

Cancer is a significant cause of mortality in patients undergoing hemodialysis.
Limited data exists on the diagnosis, treatment, and prognosis of cancer in this population.
This study addresses the gap by analyzing surgical practices and outcomes in hemodialysis patients with cancer.

Purpose of the Study:

To analyze surgical practice patterns and outcomes for cancer patients on hemodialysis.
To compare these outcomes with those of general cancer patients.
To identify factors associated with mortality in hemodialysis cancer patients.

Main Methods:

A nationwide registry study in Japan (2010-2012) of hemodialysis patients diagnosed with common cancers.
Inclusion of 502 patients across 20 hospitals.
Analysis of 3-year overall survival rates and Cox regression for mortality factors.

Main Results:

Surgery was performed in 74% of patients; 57% were asymptomatic at diagnosis.
Patients undergoing surgery had significantly higher 3-year survival (83%) compared to non-surgery (32%).
Survival rates for hemodialysis cancer patients were comparable to general cancer patients, with non-cancer deaths predominating in the surgery group.

Conclusions:

Cancer prognosis in hemodialysis patients may be similar to that of the general cancer population.
Surgery appears to be a safe and effective treatment option, improving survival.
Early cancer detection through screening is crucial for better outcomes in hemodialysis patients.